Research & Development
FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis
14 September 2026 - Japanese pharmaceutical company Takeda (TSE:4502) (NYSE:TAK) said on Monday that the US Food and Drug Administration (FDA) has accepted its new drug application for zasocitinib (TA...
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
14 September 2026 - Biotechnology company Armata Pharmaceuticals Inc (NYSE American: ARMP) reported on Monday that it has received U.S. Food and Drug Administration Breakthrough Therapy designation fo...
GSK reports positive Jideytro data supporting potential first-line lung cancer use
14 September 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) on Monday reported positive registrational Phase I/II ARROS-1 data for Jideytro (zidesamtinib) in previously untreated ROS1...
Eloxx Pharmaceuticals commences Phase 2b study of exaluren
14 September 2026 - Eloxx Pharmaceuticals Inc (Nasdaq:ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, announced on Friday that the firs...
Meant Health announces expansion of telehealth access for FDA-approved GLP-1 prescriptions
14 September 2026 - Meant Health, a digital health platform that connects patients with licensed clinicians for evaluation, prescription and ongoing care coaching, announced on Saturday that it is exp...
US FDA grants orphan drug designation for Lundbeck's asedebart
11 September 2026 - Danish biopharmaceutical company H. Lundbeck A/S (CPH: HLUN-B), which focuses on brain health, said on Friday it has received US Food and Drug Administration orphan drug designatio...